Jyong Biotech Ltd. has a Form F-1 registration statement on file for an initial public offering; the original was filed before the period this page covers, and the earliest filing here is an amendment filed on 2024-08-02. Amendments on record here: 8. It filed its final prospectus on 2025-06-18, at a public offering price of $7.50 per share. Each fact below is quoted from the filing named with it.
What the filings say
Listing
Our ordinary shares have been approved for listing on the Nasdaq Global Market under the symbol “MENS.”From the 424B4 filed 2025-06-18
Shares offered
This is an initial public offering of 2,666,667 ordinary shares of Jyong Biotech Ltd., par value US$0.00001 per share, by Jyong Biotech Ltd. The initial public offering price of our ordinary shares is US$7.50 per share.From the 424B4 filed 2025-06-18
Offering price
The initial public offering price is $7.50 per ordinary share.From the 424B4 filed 2025-06-18
Use of proceeds
We intend to use the net proceeds of this initial public offering to fund our future operations and debt obligations.From the 424B4 filed 2025-06-18
Timeline
| Filed | What it is | Filing |
|---|---|---|
| 2024-08-02 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-09-16 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-10-04 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-11-01 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-11-21 | Registration statement amended (foreign issuer) | F-1/A |
| 2024-12-19 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-02-06 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-03-11 | Registration statement amended (foreign issuer) | F-1/A |
| 2025-06-18 | Final prospectus filed: the offering is priced | 424B4 |
Tools for this story
Each opens in a new tab, filled in for Jyong Biotech Ltd.. With no account yet, you sign up free and land on the result.
Where this comes from
A company that wants to sell shares to the public in the United States files a registration statement with the SEC: Form S-1 for a US company, Form F-1 for a foreign one. It amends that statement as the figures and terms are filled in, usually adding the expected price range shortly before the offering. Once the offering is priced it files its final prospectus under Rule 424(b)(4). A company that decides not to go ahead can ask for the registration statement to be withdrawn on Form RW.
Every row on this page is one of those filings, linked to the filing itself. The facts are the company's own sentences, quoted from the filing named beside each one and never reworded; where no filing states a fact in a sentence that can be read exactly, this page leaves it out. A filing is the company's statement of its plans and its figures, not a verification of them, and nothing here is investment advice.